SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Spyre Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$84.72+4.82 (+6.03%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Spyre Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Development fee and royalty | $0 | $0 | $886.00K | $2.33M | $6.74M | – | – | – | – |
| License | – | – | $0 | $0 | $12.00M | $0 | $0 | – | – |
| Development Fee | – | – | – | $2.33M | $6.74M | $0 | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Spyre Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.